Raptor Pharma (RPTP) Gets Positive Opinion from EMAs COMP for Cystinosis Treatment DR Cysteamine
Raptor Pharmaceutical Corp. (Nasdaq: RPTP), announced that the European Medicines Agency's ("EMA") Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion recommending orphan medicinal product designation for DR Cysteamine for the potential treatment of cystinosis. DR Cysteamine is Raptor's proprietary, delayed-release,...
Get Alerted When News Hits On This Stock - FREE!